Print Friendly Page
Protocol No. RTOG0538
Principal Investigator Anderson, Bethany
Age Group Adult
Sponsor Type National
Title Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Objective The purpose of this study is to compare the effects, good and/or bad, of two different ways to give radiation therapy. One of the ways is experimental, while one of them is standard. The experimental way of giving the radiation therapy is once a day with a high dose of radiation for 7 weeks. The standard way of giving the radiation therapy is to give it twice a day for 3 weeks. Everyone will get the chemotherapy with cisplatin or carboplatin and etoposide, which has been established through clinical trials to be standard drugs (chemotherapy) for your type of cancer. The exact doses of the chemotherapy have not been completely standardized and you will be receiving a commonly used dosing schedule. It is not known what the added side effects are using this dose of chemotherapy with either of the radiotherapy regimens.
Description You will be "randomized" into one of the study groups described below. Randomization means that you are put into a group by chance. A computer program will place you in one of the study groups. Neither you nor your doctor can choose the group you will be in. You will have an equal chance of being placed in either group. Those in Group 1 will receive the standard or usual dose of radiation therapy which is radiation therapy twice a day for 5 days each week, for about 3 weeks, along with chemotherapy. Those in Group 2 will receive a higher than standard dose of radiation therapy once a day for 5 days each week for about 7 weeks along with chemotherapy. Click here for more info
Proven diagnosis of small cell lung cancer, limited stage.
Patients must have measurable disease.
No prior radiation or chemotherapy. (Exceptions apply for patients that have enrolled in trial CALGB 30610).
Patients with complete surgical resection of disease are not eligible.
Applicable Disease Sites Lung
Therapies Involved Cytotoxic Chemotherapy; Other; Radiotherapy
Drugs Involved carboplatin; cbdca (carboplatin); cis-diamminedichloroplatinum (cisplatin); cisplatin; etoposide; paraplatin (carboplatin); platinol (cisplatin); platinum (cisplatin); vepesid (etoposide); vp-16 (etoposide)
Participating Institutions Aspirus UW Cancer Center (formerly Riverview Hospital); Johnson Creek, UW Cancer Center; UW Hospital and Clinics